News
Lilly moves Crohn's drug into phase 3, faces safety setback ...
Eli Lilly has had a mixed few days, posting promising trial results for mid-stage Crohn’s disease drug mirikizumab, undercutting a key insulin from Sanofi in the US, but facing safety conce
